All In Biotech

NDA 217677 · Springworks

Ogsiveo

Nirogacestat Hydrobromide · Oral · Gamma Secretase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Nov 27, 2023: To treat adults with progressing desmoid tumors who require systemic treatment

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Nov 27, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

923

302 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2026.

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. ( 1 )

Mechanism: Nirogacestat is a gamma secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
  • OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 100MG BASE · TABLET, ORAL · Prescription
  • OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 150MG BASE · TABLET, ORAL · Prescription
  • OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 50MG BASE · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Nirogacestat Hydrobromide" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea323
  • nausea203
  • fatigue177
  • rash120
  • product dose omission issue93
  • headache90
  • vomiting82
  • stomatitis61
  • cough50
  • pruritus48
  • alopecia45
  • intentional underdose42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20212
202215
202322
2024563
2025156
2026164

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ogsiveo (Nirogacestat Hydrobromide)

2024 spending

$20.0M

Beneficiaries

154

766 claims

Per beneficiary

$130,006

$278.36 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$428,916
2024$20,020,868

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Springworks

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.